Entact Bio Launches with $81 Million Series A to Develop Precision Medicines for Targeted Protein Enhancement

  • Launch fueled by syndicate of blue-chip investors co-led by Qiming Venture Partners USA and venBio Partners
  • Company’s proprietary end-to-end Encompass™ platform designs enhancement-targeting chimeric (ENTAC™) molecules
  • Founding team comprised of world-class scientific leaders

Entact Bio, the company pioneering the development of precision medicines that enhance the function of key proteins, today announced it has raised $81 million in Series A financing to advance its proprietary Encompass™ platform for developing enhancement-targeting chimeric (ENTAC™) molecules.

The round was co-led by Qiming Venture Partners USA and venBio Partners, with participation by new investors Abingworth, Brandon Capital, Janus Henderson Investors, Logos Capital, Surveyor Capital (a Citadel company), and WEHI (Walter and Eliza Hall Institute of Medical Research), and founding investors 4BIO Capital and Arkin Bio Ventures.

“Our aim is to provide new options for patients by developing precision medicines that enhance the function of beneficial proteins rather than eliminating or blocking proteins that contribute to disease,” said Victoria Richon, CEO of Entact Bio. “To transform this vision into reality, we have built Encompass, a proprietary platform for creating therapeutics that harness the cell’s mechanism for enhancing protein function. These ENTAC medicines will make an important difference for patients whose needs aren’t adequately met by today’s treatments.”

Richon, a scientifically trained executive with 20 years of experience and expertise in company and team building, has a track record of discovering and developing novel therapies. Most recently, as founding president and CEO of Ribon Therapeutics, she led teams to develop multiple first-in-class drugs with novel mechanisms of action from inception to clinical testing.

With broad utility across disease types, ENTACs have significant potential to expand the druggable space and address unmet medical needs. Many diseases occur when there is a functional problem with a beneficial protein that is critical to cell health. These illnesses are challenging to treat with conventional small molecules, which are typically designed to inhibit proteins that are contributing to disease rather than to enhance the function of beneficial proteins…


Precision Medicine


Entact Bio



This is a unique website which will require a more modern browser to work!

Please upgrade today!